Patterns of blood product use among patients with myelodysplastic syndrome

Abstract Abstract 4849 Many patients with myelodysplastic syndrome (MDS) experience cytopenias that require blood product support. The extent to which MDS patients utilize blood products following diagnosis is unknown. The objective of this study was to characterize the use of blood products among recently diagnosed MDS patients in western Washington State. Records from the NCI's Surveillance, Epidemiology, and End Results (SEER) cancer registry for western Washington State were searched for patients diagnosed with MDS between 2001 and 2007. These records were linked to Puget Sound Blood Center (PSBC) database records. The PBSC is the major supplier of blood products for the Washington SEER region. SEER identified a total of 781 newly diagnosed patients during 2001-2007. The average age was 72.84, 76% were over age 65 and 55% were over age 75. Fifty-eight percent were male and 88% were white race. The most common MDS subtypes included refractory anemia (24%) and refractory anemia with excess blasts (21%); 33% had no specified subtype. Three hundred seventy-six patients (48%) received at least one blood product within 12 months of diagnosis; packed red blood cells (RBCs) (n=361 persons) and platelets (n=222 persons) were most commonly transfused. Among those receiving at least one transfusion of RBCs or one transfusion of platelets respectively, patients received an average of 15.40 units of RBCs and 15.37 units of platelets over 12 months from diagnosis; of these patients, the highest quartile used an average of 39.84 RBCs and 33.81 platelets per person. The proportion of MDS patients receiving any RBCs within 12 months of diagnosis increased from 24% in 2001 to 54% in 2007. Platelet use within 12 months of diagnosis increased from 12% of patients in 2001 to 39% in 2007. Among those receiving at least one platelet transfusion or at least one red blood cell transfusion within 12 months of diagnosis the number of products transfused increased over time, from an average of 8.00 platelet units (SD 5.77) and 8.85 units of RBCs (SD 11.21) in 2001 to 14.12 platelet units (SD 20.31) and 15.98 units RBCs (SD 19.35) in 2007 (p<0.0001, p<0.0001, respectively). Approximately half of newly diagnosed MDS patients receive at least one blood product in the first 12 months following diagnosis. Blood product use has increased substantially from 2001 to 2007, in terms of both the proportion of patients receiving them and the number of transfusions per person. Further study is needed to determine the factors leading to more aggressive use of blood products in these patients. Disclosures No relevant conflicts of interest to declare.

Download Full-text

Predictive Factors for High Blood Product Use in Patients with Acute Stanford Type A Dissection

10.1055/s-0040-1705504 ◽

2020 ◽

Author(s):

M. J. Schafigh ◽

M. Hamiko ◽

W. Schiller ◽

H. Treede ◽

C. Probst

Keyword(s):

Predictive Factors ◽

Blood Product ◽

Type A ◽

Product Use ◽

Type A Dissection

Download Full-text

Faculty Opinions recommendation of Blood product use in trauma resuscitation: plasma deficit versus plasma ratio as predictors of mortality in trauma (CME).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13091956.14415058 ◽

2011 ◽

Author(s):

Mike Murphy ◽

Nikki Curry

Keyword(s):

Blood Product ◽

Trauma Resuscitation ◽

Plasma Ratio ◽

Predictors Of Mortality ◽

Product Use

Download Full-text

Abnormal Calcium Levels During Trauma Resuscitation Are Associated With Increased Mortality, Increased Blood Product Use, and Greater Hospital Resource Consumption

Anesthesia & Analgesia ◽

10.1213/ane.0000000000002312 ◽

2017 ◽

Vol 125 (3) ◽

pp. 895-901 ◽

Cited By ~ 19

Author(s):

Emily J. MacKay ◽

Michael D. Stubna ◽

Daniel N. Holena ◽

Patrick M. Reilly ◽

Mark J. Seamon ◽

...

Keyword(s):

Blood Product ◽

Resource Consumption ◽

Hospital Resource ◽

Trauma Resuscitation ◽

Product Use

Download Full-text

The Impact of Perioperative Viscoelastic Test Application on Blood Product Usage and Outcome in Cardiac Surgery; Regional Cardiac Surgery Center Experience

Journal of Cardio-Vascular-Thoracic Anaesthesia and Intensive Care Society ◽

10.5222/gkdad.2021.78557 ◽

2021 ◽

Author(s):

Murat Aksun ◽

Saliha Aksun ◽

Mehmet Ali Çoşar ◽

Elif Neziroğlu ◽

Senem Girgin ◽

...

Keyword(s):

Cardiac Surgery ◽

Clinical Experience ◽

Heart Surgery ◽

Blood Product ◽

Open Heart Surgery ◽

Control Group ◽

Open Heart ◽

Blood Products ◽

Product Use ◽

The Impact

Objective: Thromboelastography (TEG) is a diagnostic modality that gives information about coagulation. Despite all blood-preserving precautions in open heart surgery there are blood losses and the use of blood and blood products becomes inevitable. TEG is mostly not available in every center and habits, trends and clinical experience in blood use create the possibility of causing unnecessary use of blood and blood products. In this study, it was aimed to determine the effect of the use of thromboelastography on the use of blood and blood products in cardiac surgery. Methods: Two hundred patients between 18-70 years old who underwent open heart surgery were included in the study. After the cardiopulmonary bypass (CPB), the cases were confirmed to have an Activated Clotting Time (ACT) value in the range of 120-150 sec after protamine administration. In 100 patients in the TEG group, the coagulation status was evaluated with TEG and it was decided how to apply blood and blood product use. Blood and blood product use was applied to 100 patients in the control group based on clinical experience and foresight. The total amount of blood and blood product used, fluid balance, need for inotropics, mechanical ventilator time, complications, duration of intensive care and discharge times were recorded. Results: Use of Fresh Frozen Plasma (FFP) at the after CPB in the TEG group was statistically significantly lower than that of the control group FFP (p<0.05). Postoperative FFP and postoperative platelet use in the study group were statistically significantly lower than in the postoperative FFP and postoperative platelet values of the control group (p <0.05). Conclusion: The use of thromboelastography is a very useful monitoring in terms of reducing FFP use after CPB and reducing FFP and platelet usage in the postoperative period. In this way, the unnecessary use of blood and blood products can be prevented.

Download Full-text

Comparison of blood product use and costs with use of 3-factor versus 4-factor prothrombin complex concentrate for off-label indications

American Journal of Health-System Pharmacy ◽

10.2146/ajhp180076 ◽

2018 ◽

Vol 75 (15) ◽

pp. 1103-1109 ◽

Cited By ~ 3

Author(s):

Jessica DeAngelo ◽

Daniel H. Jarrell ◽

Richard Cosgrove ◽

James Camamo ◽

Christopher J. Edwards ◽

...

Keyword(s):

Prothrombin Complex Concentrate ◽

Blood Product ◽

Factor Versus ◽

Off Label ◽

Product Use

Download Full-text

Blood product support

Oxford Handbook of Cancer Nursing ◽

10.1093/med/9780198569244.003.0039 ◽

2007 ◽

pp. 501-510

Keyword(s):

Blood Product ◽

Intensive Chemotherapy ◽

Blood Products ◽

Product Use ◽

Remission Rates ◽

Nurses Role ◽

British Committee

Blood products 502 The nurses' role in blood product transfusions 508 The introduction of safe, reliable blood products has enabled the development of intensive chemotherapy programmes for a variety of malignancies. This has led to significantly improved remission rates. It must be remembered however that blood product use is not without risks, and that these are a very expensive resource. The pool of acceptable donors is also diminishing because of more stringent screening. Blood products should only be used in appropriate situations in consultation with national and local guidelines. (See British Committee for Standards in Haematology, BCSH...

Download Full-text